Skip to main content

NICE TAs

21/04/2020
TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
21/04/2020
TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line
21/04/2020
TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
16/04/2020
TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
16/04/2020
TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
16/04/2020
TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
16/04/2020
TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
15/04/2020
TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
05/03/2020
TA367: Vortioxetine for treating major depressive episodes

Published date: We reviewed the evidence in November 2018. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA272: Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Published date: We reviewed the evidence in January 2016. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA179: Sunitinib for the treatment of gastrointestinal stromal tumours

Published date: We reviewed the evidence in July 2017. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Published date: We reviewed the evidence in March 2018. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA482: Immunosuppressive therapy for kidney transplant in children and young people

Published date: Next review: 2020

05/03/2020
TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma

Published date: In July 2017, we decided that we will review the evidence within 6 months of publication of the PIX306 trial results.

05/03/2020
TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer

Published date: Next review: 2019

05/03/2020
TA610: Pentosan polysulfate sodium for treating bladder pain syndrome

Published date: Next review: 2022

There is a simple discount patient access scheme for pentosan polysulfate sodium

05/03/2020
TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin

Published date: Next review: 2019 This guidance replaces TA309.

05/03/2020
TA339: Omalizumab for previously treated chronic spontaneous urticaria

Published date: 

We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA494: Naltrexone–bupropion for managing overweight and obesity

Published date: We reviewed the evidence in January 2020. We found nothing new that affects the recommendations in this guidance.

05/03/2020
TA318: Lubiprostone for treating chronic idiopathic constipation

This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).

Follow AWTTC: